Drug intelligence / Profile preview

Onco-Rash

Development stage: Unknown
Lead developer: Hospices Civils de Lyon
Modality: Small Molecules
Administration: Topical

Overview

Onco-Rash is a topical cosmetic cream developed by Hospices Civils de Lyon to mitigate skin toxicities, such as rashes and epidermal fragilization, in patients receiving anti-EGFR (Epidermal Growth Factor Receptor) cancer therapies. These therapies, commonly used for non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancer, often cause dermatological side effects that can lead to treatment interruption. Onco-Rash is designed to preserve skin integrity, improve patient quality of life, and facilitate adherence to primary oncological treatments. It was evaluated in the OPERA clinical trial against a neutral control cream (Onco-Neutre).

Brand names: Onco-Rash
Other names: Onco-Rash cream

Beyond the preview

Go deeper on Onco-Rash.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onco-Rash.

Explore the full profile